Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index; 252 of the 329 sources its claims cite were checked for support.

Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease

Open access
Terzioglu, Gizem, Young-Pearse, Tracy L. · 2023 · Molecular Neurodegeneration

Abstract

Recent genetic studies on Alzheimer’s disease (AD) have brought microglia under the spotlight, as loci associated with AD risk are enriched in genes expressed in microglia. Several of these genes have been recognized for their central roles in microglial functions. Increasing evidence suggests that SHIP1, the protein encoded by the AD-associated gene INPP5D, is an important regulator of microglial phagocytosis and immune response. A recent study from our group identified SHIP1 as a negative regulator of the NLRP3 inflammasome in human iPSC-derived microglial cells (iMGs). In addition, we found evidence for a connection between SHIP1 activity and inflammasome activation in the AD brain. The NLRP3 inflammasome is a multiprotein complex that induces the secretion of pro-inflammatory cytokines as part of innate immune responses against pathogens and endogenous damage signals. Previously published studies have suggested that the NLRP3 inflammasome is activated in AD and contributes to AD-related pathology. Here, we provide an overview of the current understanding of the microglial NLRP3 inflammasome in the context of AD-related inflammation. We then review the known intracellular functions of SHIP1, including its role in phosphoinositide signaling, interactions with microglial phagocytic receptors such as TREM2 and evidence for its intersection with NLRP3 inflammasome signaling. Through rigorous examination of the intricate connections between microglial signaling pathways across several experimental systems and postmortem analyses, the field will be better equipped to tailor newly emerging therapeutic strategies targeting microglia in neurodegenerative diseases.

Overview

CoChat Summary

TL;DR

This narrative review synthesizes evidence that SHIP1, encoded by the Alzheimer's disease (AD) risk gene INPP5D, acts as a negative regulator of microglial activation and of the NLRP3 inflammasome, and proposes that reduced SHIP1 activity links phosphoinositide signaling, phagocytic receptor pathways (TREM2, TLR4, FcγR, CR3, TAM receptors), and inflammasome-driven neuroinflammation in AD. It argues that SHIP1's effects are context- and disease-stage-dependent, leaving open whether therapeutic strategies should aim to increase or decrease SHIP1 activity.

Key findings

  • The authors' group previously found that acute pharmacological inhibition of SHIP1 phosphatase activity or genetic loss of one copy of INPP5D in human iPSC-derived microglia (iMGs) induced IL-18 and IL-1β secretion that was blocked by the NLRP3 inhibitor MCC950 and by caspase-1 inhibitors; despite increased cytokine secretion, pro-IL-1β mRNA was lowered, suggesting SHIP1 reduction promotes the activation step while feedback-inhibiting the priming step.
  • In post-mortem AD brain, lower aqueous-soluble SHIP1 levels were significantly associated with elevated IL-18 protein, and lower SHIP1 immunoreactivity correlated with a higher percentage of microglia containing ASC specks; SHIP1 localization shifted from diffuse to punctate patterns, and mass spectrometry showed reduced peptides encoding the SHIP1 phosphatase domain in AD brain.
  • NLRP3 inflammasome activation is implicated in AD pathology: Aβ (fibrillar and oligomeric) and aggregated tau activate the inflammasome, ASC specks can cross-seed Aβ aggregation, and Nlrp3 or Casp1 ablation in APP/PS1 mice rescued spatial memory, LTP suppression and spine loss and decreased plaque deposition, while MCC950 reduced plaque numbers and improved cognition in APP/PS1 mice.
  • Mouse studies of Inpp5d reduction show largely beneficial effects (increased phagocytosis of apoptotic neurons and Aβ42, increased plaque-associated microglia, plaque compaction, rescued spontaneous alternation in 5xFAD), but effects on plaque burden are contradictory across studies (increased, decreased, or unchanged depending on model and timing).

Methods

  • Narrative review; no primary experiments reported. The authors synthesize published human post-mortem, human iPSC-derived microglia, and rodent model literature, including their own prior study (Chou et al., Nat Commun 2023).
  • Scope: microglial biology, NLRP3 inflammasome assembly and two-step activation, phosphoinositide/PI3K-Akt signaling, SHIP1 domain structure and post-translational regulation, SHIP1 interactions with TREM2/DAP12, TLR4/MyD88, NOD2, FcγRIIA/IIB, CR3 and TAM receptors, INPP5D genetics and isoform expression, and consequences of microglial inflammasome activation on neurons, astrocytes and oligodendrocytes.
  • No systematic search strategy, inclusion criteria, or quantitative synthesis is described.

Limitations

  • Stated by the paper: evidence on whether to increase or decrease SHIP1 activity is "seemingly contradictory"; the authors attribute divergent mouse plaque-load results to differences in disease stage at which Inpp5d is reduced and to differences among AD mouse models, and note possible genuine species differences or unknown extenuating factors.
  • Stated by the paper: it is unclear whether and how the AD-associated INPP5D SNPs (rs35349669, rs10933431, rs7597763, rs61068452) affect INPP5D mRNA levels or splicing; one study found increased expression of a truncated isoform lacking the phosphatase domain, so increased INPP5D expression may not mean increased SHIP1 activity.
  • Stated by the paper: methods to measure SHIP1 activity in microglia in postmortem brain are lacking, and further studies are needed; the authors also note that astrocyte-state studies relied on the binary "A1/A2" framework, which does not capture astrocyte diversity.
  • Evident from the text: as a narrative review it presents no new data, and several key mechanistic claims (e.g., SHIP1 inhibition of TREM2 signaling) derive from non-microglial cells such as osteoclasts and macrophages, with the authors noting that mechanisms in microglia remain to be clarified.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13024-023-00674-9

Cites

202 of 202 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 NLRP3 inflammasome activation involves two steps. In the priming step, activation of TLR4, TNFR or IL-1R1 leads to activation of NF-kB, which subsequently translocates to the nucleus and induces the transcription of pro-IL-1β, ASC (also known as PYCARD) and NLRP3. NLRP3 is autoinihibted in the cytosol and remains in the autoinhibited state after the priming step. An activating signal is necessary to release the autoinhibition. Activated NLRP3 can undergo oligomerization through homotypic NACHT domain interactions to form the inflammasome complex. NLRP3 oligomers induce the filament assembly of ASC (PYCARD) into ASC specks through homotypic PYD interactions. ASC specks act as a molecular platform to recruit pro-caspase-1 through homotypic CARD interactions. Pro-caspase-1 undergoes autoproteolysis to generate active caspase-1, which can cleave pro-forms of IL-1β and IL-18 into their mature forms. Caspase-1 can also cleave gasdermin D (GSDMD) into its N-terminal fragment (GSDMD-N), which translocates to the plasma membrane and forms a pore, through which IL-1β and IL-18 are released into the extracellular space (ECS). NLRP3, nucleotide-binding domain (NOD)-like receptor protein 3; ASC, apoptosis-associated speck-like protein; PYD, pyrin-like domain; CARD, caspase recruitment domain; LRR, leucine-rich repeat. Figure created in BioRender.com [55, 61, 62]
Fig. 1 NLRP3 inflammasome activation involves two steps. In the priming step, activation of TLR4, TNFR or IL-1R1 leads to activation of NF-kB, which subsequently translocates to the nucleus and induces the transcription of pro-IL-1β, ASC (also known as PYCARD) and NLRP3. NLRP3 is autoinihibted in the cytosol and remains in the autoinhibited state after the priming step. An activating signal is necessary to release the autoinhibition. Activated NLRP3 can undergo oligomerization through homotypic NACHT domain interactions to form the inflammasome complex. NLRP3 oligomers induce the filament assembly of ASC (PYCARD) into ASC specks through homotypic PYD interactions. ASC specks act as a molecular platform to recruit pro-caspase-1 through homotypic CARD interactions. Pro-caspase-1 undergoes autoproteolysis to generate active caspase-1, which can cleave pro-forms of IL-1β and IL-18 into their mature forms. Caspase-1 can also cleave gasdermin D (GSDMD) into its N-terminal fragment (GSDMD-N), which translocates to the plasma membrane and forms a pore, through which IL-1β and IL-18 are released into the extracellular space (ECS). NLRP3, nucleotide-binding domain (NOD)-like receptor protein 3; ASC, apoptosis-associated speck-like protein; PYD, pyrin-like domain; CARD, caspase recruitment domain; LRR, leucine-rich repeat. Figure created in BioRender.com [55, 61, 62]CC BY · PubMed Central
Fig. 2 SHIP1 is a phosphatase involved in phosphoinositide signaling. Activation of a receptor tyrosine kinase (RTK) recruits the p85 subunit of phosphotidylinositol-3 kinase (PI3K). PI3K generates PI(3,4,5)P3 at the plasma membrane by phosphorylating PI(4,5)P2. SYNJ1 can dephosphorylate PI(4,5)P2 back into its precursor, PI4P. PI(3,4,5)P3 can activate Akt, which can activate various downstream targets, one of which is IKKα of the IKK kinase complex. IKKα activation leads to phosphorylation of IkB, followed by the ubiquitin-mediated proteasomal degradation of IkB, which enables the NF-kB complex to translocate to the nucleus. The NF-kB complex can activate the transcription of its numerous target genes, including genes involved in immune response. SHIP1 can negatively regulate PI3K/Akt signaling. SHIP1 binds to PI(3,4,5)P3 via its PH-L domain and dephosphorylates PI(3,4,5)P3 via its 5’ phosphatase catalytic domain to generate PI(4,5)P2. C2 domain of SHIP1 can bind to PI(4,5)P2, which is thought to allosterically regulate SHIP1’s phosphatase activity. SH2 domain can dock onto phosphorylated tyrosine residues to regulate the activity of receptors containing immunoreceptor tyrosine activating/inhibiting motif (ITAMs/ITIMs). This domain is also important for SHIP1’s localization within the cell. SHIP1 can be phosphorylated at Ser440 within the 5’ phosphatase domain by PKA to increase the phosphatase activity. Phosphorylation of SHIP1 at Tyr1022 within the NPxY motif allows binding with SHIP1’s own SH2 domain, which may mediate its dimerization or oligomerization. ECS, extracellular space; SH2, src homology 2, PH-L, plectrin homology-like. Figure created in BioRender.com [87, 88, 91, 106, 107, 128]
Fig. 2 SHIP1 is a phosphatase involved in phosphoinositide signaling. Activation of a receptor tyrosine kinase (RTK) recruits the p85 subunit of phosphotidylinositol-3 kinase (PI3K). PI3K generates PI(3,4,5)P3 at the plasma membrane by phosphorylating PI(4,5)P2. SYNJ1 can dephosphorylate PI(4,5)P2 back into its precursor, PI4P. PI(3,4,5)P3 can activate Akt, which can activate various downstream targets, one of which is IKKα of the IKK kinase complex. IKKα activation leads to phosphorylation of IkB, followed by the ubiquitin-mediated proteasomal degradation of IkB, which enables the NF-kB complex to translocate to the nucleus. The NF-kB complex can activate the transcription of its numerous target genes, including genes involved in immune response. SHIP1 can negatively regulate PI3K/Akt signaling. SHIP1 binds to PI(3,4,5)P3 via its PH-L domain and dephosphorylates PI(3,4,5)P3 via its 5’ phosphatase catalytic domain to generate PI(4,5)P2. C2 domain of SHIP1 can bind to PI(4,5)P2, which is thought to allosterically regulate SHIP1’s phosphatase activity. SH2 domain can dock onto phosphorylated tyrosine residues to regulate the activity of receptors containing immunoreceptor tyrosine activating/inhibiting motif (ITAMs/ITIMs). This domain is also important for SHIP1’s localization within the cell. SHIP1 can be phosphorylated at Ser440 within the 5’ phosphatase domain by PKA to increase the phosphatase activity. Phosphorylation of SHIP1 at Tyr1022 within the NPxY motif allows binding with SHIP1’s own SH2 domain, which may mediate its dimerization or oligomerization. ECS, extracellular space; SH2, src homology 2, PH-L, plectrin homology-like. Figure created in BioRender.com [87, 88, 91, 106, 107, 128]CC BY · PubMed Central
Fig. 3 SHIP1 regulates multiple receptors expressed in microglia and the microglial NLRP3 inflammasome. (A) TREM2 activation recruits p85 subunit of PI3K to the immunoreceptor tyrosine activating motif (ITAM) of DAP12. SHIP1 inhibits downstream activity of TREM2/DAP12 by binding to the immunoreceptor tyrosine activating motif (ITAM) of DAP12, preventing the association of p85 with DAP12, in osteoclasts. (B) SHIP1 inhibits the association of TLR4 with its adaptor protein MyD88 in macrophages. TLR4/MyD88 signaling leads to activation of NF-kB by inducing degradation of IΚB, which is also inhibited by SHIP1. (C) SHIP1 inhibits phagocytosis mediated by CR3 and FCγRIIA in macrophages. SHIP1 binds to the ITAM of FCγRIIA, inhibiting the downstream PI3K signaling. SHIP1 can also bind to the immunoreceptor tyrosine inhibitory motif (ITIM) of the inhibitory receptor FCγRIIB, which enhances FCγRIIB-mediated inhibition of phagocytosis. The exact mechanism of how SHIP1 inhibits CR3 is currently unknown. (D) SHIP1 inhibits the activation of the NLRP3 inflammasome. Pharmacological inhibition of SHIP1 or genetic reduction of INPP5D activates the NLRP3 inflammasome in human iPSC-derived microglial cells (iMGs), resulting in increased secretion of IL-1β and IL-18. On the other hand, loss of SHIP1 inhibits the upregulation of pro-IL-1β, suggesting that reduction of SHIP1 activity may induce inflammasome activation while inhibiting the priming step in some contexts. ECS, extracellular space. Figure created in BioRender.com [114, 121, 137, 138, 161, 197]
Fig. 3 SHIP1 regulates multiple receptors expressed in microglia and the microglial NLRP3 inflammasome. (A) TREM2 activation recruits p85 subunit of PI3K to the immunoreceptor tyrosine activating motif (ITAM) of DAP12. SHIP1 inhibits downstream activity of TREM2/DAP12 by binding to the immunoreceptor tyrosine activating motif (ITAM) of DAP12, preventing the association of p85 with DAP12, in osteoclasts. (B) SHIP1 inhibits the association of TLR4 with its adaptor protein MyD88 in macrophages. TLR4/MyD88 signaling leads to activation of NF-kB by inducing degradation of IΚB, which is also inhibited by SHIP1. (C) SHIP1 inhibits phagocytosis mediated by CR3 and FCγRIIA in macrophages. SHIP1 binds to the ITAM of FCγRIIA, inhibiting the downstream PI3K signaling. SHIP1 can also bind to the immunoreceptor tyrosine inhibitory motif (ITIM) of the inhibitory receptor FCγRIIB, which enhances FCγRIIB-mediated inhibition of phagocytosis. The exact mechanism of how SHIP1 inhibits CR3 is currently unknown. (D) SHIP1 inhibits the activation of the NLRP3 inflammasome. Pharmacological inhibition of SHIP1 or genetic reduction of INPP5D activates the NLRP3 inflammasome in human iPSC-derived microglial cells (iMGs), resulting in increased secretion of IL-1β and IL-18. On the other hand, loss of SHIP1 inhibits the upregulation of pro-IL-1β, suggesting that reduction of SHIP1 activity may induce inflammasome activation while inhibiting the priming step in some contexts. ECS, extracellular space. Figure created in BioRender.com [114, 121, 137, 138, 161, 197]CC BY · PubMed Central

Verification

Claims the paper makes

145 Valid · 14 Not valid · 30 Not checked · 29 Own results and interpretations

108 more claims · 73 with their cited sources checked

Create a free account to see all 218 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 93

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 200 references

Cited by

See all 91

Metadata

Authors
Terzioglu, G., & Young-Pearse, T. L.
Venue
Molecular Neurodegeneration
Published
2023-11-29
Volume
18
Issue
1
Pages
89-89
ISSN
1750-1326 (ISSN-L)
OpenAlex
W4389109479
Cited by
91
References
200
Citations by year
2026: 32 · 2025: 35 · 2024: 24
FWCI
2.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
NIH (R01AG055909, RF1NS117446, U01AG072572)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, microglia, SHIP1, INPP5D, NLRP3 inflammasome, microglial phagocytosis, TREM2, phosphoinositide signaling, neuroinflammation, innate immunity
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases, Alzheimer Disease, Brain, Humans, Microglia, Inflammasomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13024-023-00674-9
The paper
Terzioglu, G., & Young-Pearse, T. L. (2023). Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-023-00674-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.